<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33094561</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1582-4934</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>24</Volume>
            <Issue>23</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cellular and molecular medicine</Title>
          <ISOAbbreviation>J Cell Mol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>IGF2BP3 facilitates cell proliferation and tumorigenesis via modulation of JAK/STAT signalling pathway in human bladder cancer.</ArticleTitle>
        <Pagination>
          <StartPage>13949</StartPage>
          <EndPage>13960</EndPage>
          <MedlinePgn>13949-13960</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/jcmm.16003</ELocationID>
        <Abstract>
          <AbstractText>Insulin-like growth factor-2 messenger RNA-binding protein 3 (IGF2BP3) has been reported to contribute to tumorigenesis in several human cancers. However, the biological functions of IGF2BP3 in bladder cancer are poorly understood. We investigated the relation between IGF2BP3 expression and prognosis of bladder cancer patients. Cell proliferation, cell cycle and cell apoptosis assays were performed to assess IGF2BP3 functions. The results showed that IGF2BP3 was overexpressed in bladder cancer tissues compared with that in normal bladder tissues, and its higher expression was closely correlated with poor prognosis in bladder cancer patients. Overexpression of IGF2BP3 markedly promoted cell proliferation and cell cycle progression and inhibited cell apoptosis, while knockdown of IGF2BP3 notably suppressed the proliferation, promoted cell apoptosis and induced cell cycle arrest at the G0/G1 phase. Mechanistically, we revealed that IGF2BP3 promotes the activation of the JAK/STAT pathway in bladder cancer cells. Moreover, the JAK/STAT inhibitor dramatically blocked the tumour-promoting activity of IGF2BP3. Tumour growth in vivo was also suppressed by knocking down of IGF2BP3. Hence, IGF2BP3 facilitated bladder cancer cell proliferation by activating the JAK/STAT signalling pathway. These findings suggest that IGF2BP3 exhibits an oncogenic effect in human bladder cancer progression.</AbstractText>
          <CopyrightInformation>© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Wei</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0001-8311-8490</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Yuanyuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zha</LastName>
            <ForeName>Huihai</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xiaocheng</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fu</LastName>
            <ForeName>Bin</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Ju</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Gongxian</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Cell Mol Med</MedlineTA>
        <NlmUniqueID>101083777</NlmUniqueID>
        <ISSNLinking>1582-1838</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C498780">IGF2BP3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059447" MajorTopicYN="N">Cell Cycle Checkpoints</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002471" MajorTopicYN="Y">Cell Transformation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D030541" MajorTopicYN="N">Databases, Genetic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064593" MajorTopicYN="N">Heterografts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050791" MajorTopicYN="N">STAT Transcription Factors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001749" MajorTopicYN="N">Urinary Bladder Neoplasms</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">IGF2BP3</Keyword>
        <Keyword MajorTopicYN="Y">JAK/STAT</Keyword>
        <Keyword MajorTopicYN="Y">bladder cancer</Keyword>
        <Keyword MajorTopicYN="Y">prognosis</Keyword>
        <Keyword MajorTopicYN="Y">proliferation</Keyword>
      </KeywordList>
      <CoiStatement>The authors confirm that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>8</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33094561</ArticleId>
        <ArticleId IdType="pmc">PMC7753985</ArticleId>
        <ArticleId IdType="doi">10.1111/jcmm.16003</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Fernández MI, Brausi M, Clark PE, et al. Epidemiology, prevention, screening, diagnosis, and evaluation: Update of the ICUD‐SIU joint consultation on bladder cancer. World J Urol. 2019;37:3‐13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30105454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7‐30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29313949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gong Y, Woda BA, Jiang Z. Oncofetal protein IMP3, a new cancer biomarker. Adv Anat Pathol. 2014;21:191‐200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24713990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vikesaa J, Hansen TVO, Jønson L, et al. RNA‐binding IMPs promote cell adhesion and invadopodia formation. EMBO J. 2006;25:1456‐1468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1440323</ArticleId>
            <ArticleId IdType="pubmed">16541107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nielsen J, Christiansen J, Lykke‐Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin‐like growth factor II mRNA‐binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262‐1270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC116055</ArticleId>
            <ArticleId IdType="pubmed">9891060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mueller‐Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88:95‐99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10525192</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sitnikova L, Mendese G, Liu Q, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008;14:1701‐1706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18347170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu H, Bourne PA, Spaulding BO, Wang HL. High‐grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol. 2007;38:555‐563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17316760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Damasceno EAM, Carneiro FP, de Magalhães AV, et al. IMP3 expression in gastric cancer: Association with clinicopathological features and HER2 status. J Cancer Res Clin Oncol. 2014;140:2163‐2168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25323937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lok T, Chen L, Lin F, Wang HL. Immunohistochemical distinction between intrahepatic cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum Pathol. 2014;45:394‐400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24439226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jiang Z, Lohse CM, Chu PG, et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer. 2008;112:2676‐2682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2789394</ArticleId>
            <ArticleId IdType="pubmed">18412154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Burdelski C, Jakani‐Karimi N, Jacobsen F, et al. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncol Rep. 2018;39:3‐13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5783598</ArticleId>
            <ArticleId IdType="pubmed">29115542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA‐binding protein IMP3 to predict metastasis and prognosis of renal‐cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556‐564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16814207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu W, Sheng Y, Guo Y, et al. Increased IGF2BP3 expression promotes the aggressive phenotypes of colorectal cancer cells in vitro and vivo. J Cell Physiol. 2019;234:18466‐18479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30895618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhao W, Lu D, Liu L, et al. Insulin‐like growth factor 2 mRNA binding protein 3 (IGF2BP3) promotes lung tumorigenesis via attenuating p53 stability. Oncotarget. 2017;8:93672‐93687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5706827</ArticleId>
            <ArticleId IdType="pubmed">29212181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vera J, Rateitschak K, Lange F, Kossow C, Wolkenhauer O, Jaster R. Systems biology of JAK‐STAT signalling in human malignancies. Prog Biophys Mol Biol. 2011;106:426‐434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21762720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lederer M, Bley N, Schleifer C, Huttelmaier S. The role of the oncofetal IGF2 mRNA‐binding protein 3 (IGF2BP3) in cancer. Semin Cancer Biol. 2014;29:3‐13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25068994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rivera Vargas T, Boudoukha S, Simon A, et al. Post‐transcriptional regulation of cyclins D1, D3 and G1 and proliferation of human cancer cells depend on IMP‐3 nuclear localization. Oncogene. 2014;33:2866‐2875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23812426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Samanta S, Pursell B, Mercurio AM. IMP3 protein promotes chemoresistance in breast cancer cells by regulating breast cancer resistance protein (ABCG2) expression. J Biol Chem. 2013;288:12569‐12573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3642304</ArticleId>
            <ArticleId IdType="pubmed">23539627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lin C‐Y, Chen S‐T, Jeng Y‐M, et al. Insulin‐like growth factor II mRNA‐binding protein 3 expression promotes tumor formation and invasion and predicts poor prognosis in oral squamous cell carcinoma. J Oral Pathol Med. 2011;40:699‐705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23647076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jeng Y‐M, Chang C‐C, Hu F‐C, et al. RNA‐binding protein insulin‐like growth factor II mRNA‐binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology. 2008;48:1118‐1127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18802962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schaeffer DF, Owen DR, Lim HJ, et al. Insulin‐like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer. 2010;10:59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2837867</ArticleId>
            <ArticleId IdType="pubmed">20178612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yan J, Wei Q, Jian W, et al. IMP3 predicts invasion and prognosis in human lung adenocarcinoma. Lung. 2016;194:137‐146.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26608347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Suvasini R, Shruti B, Thota B, et al. Insulin growth factor‐2 binding protein 3 (IGF2BP3) is a glioblastoma‐specific marker that activates phosphatidylinositol 3‐kinase/mitogen‐activated protein kinase (PI3K/MAPK) pathways by modulating IGF‐2. J Biol Chem. 2011;286:25882‐25890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3138258</ArticleId>
            <ArticleId IdType="pubmed">21613208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bolli R, Dawn B, Xuan YT. Role of the JAK‐STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med. 2003;13:72‐79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12586443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Groner B, von Manstein V. Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017;451:1‐14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28576744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015;113:365‐371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4522639</ArticleId>
            <ArticleId IdType="pubmed">26151455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhu D, Yu Y, Wang W, et al. Long noncoding RNA PART1 promotes progression of non‐small cell lung cancer cells via JAK‐STAT signaling pathway. Cancer Med. 2019;8:6064‐6081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6792487</ArticleId>
            <ArticleId IdType="pubmed">31436388</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xiong H, Zhang Z‐G, Tian X‐Q, et al. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008;10:287‐297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2259457</ArticleId>
            <ArticleId IdType="pubmed">18320073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther. 2004;3:11‐20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14749471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin‐6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate. 2000;42:239‐242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10639195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pei X, Li M, Zhan J, et al. Enhanced IMP3 expression activates NF‐кB pathway and promotes renal cell carcinoma progression. PLoS One. 2015;10:e0124338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4412497</ArticleId>
            <ArticleId IdType="pubmed">25919292</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
